Wird geladen...
OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, us...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Neurol Disord |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5703105/ https://ncbi.nlm.nih.gov/pubmed/29204191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285617731521 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|